Celyad – previously Cardio3 BioSciences – is a biopharmaceutical company focused on translating breakthrough cell-based research into innovative therapeutics to improve the outcome of severe diseases. The Company is currently developing clinical stage cell therapies in cardiology and oncology, two healthcare segments with high unmet medical needs.
Unique therapies for transformational cures
Celyad's lead product candidate in cardiovascular disease is C-Cure®, an autologous cell therapy based on the Company's Cardiopoiesis technology platform. The Cardiopoiesis platform consists of mesenchymal cells engineered to improve their reparative capabilities for the treatment of congestive heart failure. In oncology, the company is developing CAR T-cell therapies for the treatment of various different cancers. The lead immuno-oncology product NKG2D CAR T-cell is an autologous T-cell transduced with a NKG2D receptor present on Natural Killer (NK) cells that binds to numerous types of cancer cells, including blood cancers and solid tumors.